The recent European Society of Cardiology (ESC) Congress in Stockholm, Sweden, was a great success for Bayer HealthCare. Professors Lars Ryden and Giuseppe Mancia co-chaired an exciting case-study-based programme “The cardiovascular disease prevention map – a multiroute approach”. Specialists from different fields in cardiovascular disease (CVD) discussed the evidence supporting the use ofmultiple risk assessment and management strategies, focusing on integrated therapy with Adalat® GITS, Aspirin® and Glucobay®. Despite competition from 16 other satellites running at the same time, the Bayer Cardiovascular Risk Management satellite was attended by about 270 delegates.
The contribution of each drug to the management of the other risk factors was discussed and the speakers made recommendations regarding the merits of specific treatment regimens. The importance of optimising treatment regimens and the need for tailored, combined strategies to ensure the best possible outcome were highlighted.
As always, the Bayer Cardiovascular Risk Management booth had a continuous stream of visitors. Delegates were attracted by the latest Adalat® publications from ACTION, the Aspirin Women's Health Study booklet and Glucobay® papers highlighting Glucobay® as first-line therapy for type 2 diabetes and describing its additional benefits for patients at CV risk.
